EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mesenchymal stromal cells for improvement of cardiac function following acute myocardial infarction: a matter of timing

Stéphanie Barrère-Lemaire iD, Anne Vincent iD, Christian Jorgensen, Christophe Piot, Joël Nargeot, Farida Djouad iD

Physiological Reviews · 01.04.2024 · 104 (2) · 659-725

DOI: 10.1152/physrev.00009.2023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Physiological Reviews, erschienen am 01.04.2024. Verfasst von Stéphanie Barrère-Lemaire und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Génomique Fonctionnelle, Université de Montpellier, Centre National de la Recherche Scientifique, Institut National de la Santé et de la …. Hauptthemen laut MEDLINE: Myocardial Infarction, Heart Failure, Mesenchymal Stem Cells. Die Arbeit wurde bisher 91-mal zitiert (Crossref) und nennt 634 Literaturangaben. Gefördert von: Agence Nationale de la Recherche (ANR), Fondation de France (Foundation of France), CNRS | Institut des sciences biologiques (INSB).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myocardial infarction (AMI) is the leading cause of cardiovascular death and remains the most common cause of heart failure. Reopening of the occluded artery, i.e., reperfusion, is the only way to save the myocardium. However, the expected benefits of reducing infarct size are disappointing due to the reperfusion paradox, which also induces specific cell death. These ischemia-reperfusion (I/R) lesions can account for up to 50% of final infarct size, a major determinant for both mortality and the risk of heart failure (morbidity). In this review, we provide a detailed description of the cell death and inflammation mechanisms as features of I/R injury and cardioprotective strategies such as ischemic postconditioning as well as their underlying mechanisms. Due to their biological properties, the use of mesenchymal stromal/stem cells (MSCs) has been considered a potential therapeutic approach in AMI. Despite promising results and evidence of safety in preclinical studies using MSCs, the effects reported in clinical trials are not conclusive and even inconsistent. These discrepancies were attributed to many parameters such as donor age, in vitro culture, and storage time as well as injection time window after AMI, which alter MSC therapeutic properties. In the context of AMI, future directions will be to generate MSCs with enhanced properties to limit cell death in myocardial tissue and thereby reduce infarct size and improve the healing phase to increase postinfarct myocardial performance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocardial InfarctionHeart FailureMesenchymal Stem CellsHumansMyocardiumCardiovascular Physiological Phenomena

Stichwörter der Autor:innen

apoptosiscardioprotectionconditioninginflammationmesenchymal stromal/stem cellsmyocardial infarction

Autor:innen und Institutionen

  • Institut de Génomique Fonctionnelle, Université de Montpellier, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Montpellier, France.
  • LabEx Ion Channel Science and Therapeutics, Université de Nice, Nice, France.
  • Institute of Regenerative Medicine and Biotherapies, Université de Montpellier, Institut National de la Santé et de la Recherche Médicale, Montpellier, France.
  • Centre Hospitalier Universitaire Montpellier, Montpellier, France.
  • Département de Cardiologie Interventionnelle, Clinique du Millénaire, Montpellier, France.

ORCID-Profile: Stéphanie Barrère-Lemaire, Anne Vincent, Farida Djouad

Förderung

  • Agence Nationale de la Recherche (ANR)
  • Fondation de France (Foundation of France)
  • CNRS | Institut des sciences biologiques (INSB)
  • region Occitanie prematuration
  • Région Occitanie Pyrénées-Méditerranée

Zitieren

APA

Barrère-Lemaire, S., Vincent, A., Jorgensen, C., Piot, C., Nargeot, J., & Djouad, F. (2024). Mesenchymal stromal cells for improvement of cardiac function following acute myocardial infarction: a matter of timing. Physiological Reviews, 104(2), 659-725. https://doi.org/10.1152/physrev.00009.2023

Vancouver

Barrère-Lemaire S, Vincent A, Jorgensen C, Piot C, Nargeot J, Djouad F. Mesenchymal stromal cells for improvement of cardiac function following acute myocardial infarction: a matter of timing. Physiological Reviews. 2024;104(2):659-725. doi:10.1152/physrev.00009.2023

BibTeX
@article{BarrreLemaire2024,
  author = {Barrère-Lemaire, Stéphanie and Vincent, Anne and Jorgensen, Christian and Piot, Christophe and Nargeot, Joël and Djouad, Farida},
  title = {Mesenchymal stromal cells for improvement of cardiac function following acute myocardial infarction: a matter of timing},
  journal = {Physiological Reviews},
  year = {2024},
  volume = {104},
  number = {2},
  pages = {659--725},
  doi = {10.1152/physrev.00009.2023}
}
Kostenlos starten →